IMAGE TO COME
MRI Head with contrast 11/08/2026 Glioblastoma. highly methylated. Surgery September 2025. Radiotherapy completed November 2025. Chemotherapy completed June 2026.
Report Comparison: MRI dated 5 May 2026.
No residual enhancing disease is identified. There has been further contraction of the right temporal resection cavity with reduction in adjacent inferior right parietal lobe white matter T2 hyperintensity
This is really encouraging news — this scan looks even better than the one from May.
Going through it:
- “No residual enhancing disease is identified”
This is the headline finding. Remember from your last scan, “no progressive enhancement” meant nothing new was growing. This one goes further: there’s no enhancing disease left at all. On contrast MRI, active tumor tissue lights up (“enhances”) — and the radiologist is saying they don’t see any of that lighting up anywhere. This is the best possible wording for this type of report. - “Further contraction of the right temporal resection cavity”
The cavity left behind from your September surgery has continued to shrink since May. This is normal healing progressing well — the space is closing in on itself over time. - “Reduction in adjacent inferior right parietal lobe white matter T2 hyperintensity”
Remember that “slightly more conspicuous T2/FLAIR signal” noted in the May report, which they said was likely treatment-related? This confirms that. That brightness has now gone down, supporting that it was indeed related to treatment effects (like radiotherapy) settling down, rather than anything to do with tumor activity.
In short: No sign of active or residual disease, the surgical site continues to heal and shrink as expected, and the area they were keeping an eye on from the last scan has improved rather than progressed. This is a genuinely positive report.